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MaAortic stenosis is characterized both by progressive valve narrowing and the left ventricular remodeling response that
ensues. The only effective treatment is aortic valve replacement, which is usually recommended in patients with severe
stenosis and evidence of left ventricular decompensation. At present, left ventricular decompensation is most frequently
identified by the development of typical symptoms or a marked reduction in left ventricular ejection fraction <50%.
However, there is growing interest in using the assessment of myocardial fibrosis as an earlier and more objective marker
of left ventricular decompensation, particularly in asymptomatic patients, where guidelines currently rely on non-
randomized data and expert consensus. Myocardial fibrosis has major functional consequences, is the key pathological
process driving left ventricular decompensation, and can be divided into 2 categories. Replacement fibrosis is irreversible
and identified using late gadolinium enhancement on cardiac magnetic resonance, while diffuse fibrosis occurs earlier,
is potentially reversible, and can be quantified with cardiac magnetic resonance T1 mapping techniques. There is a
substantial body of observational data in this field, but there is now a need for randomized clinical trials of myocardial
imaging in aortic stenosis to optimize patient management. This review will discuss the role that myocardial fibrosis plays
in aortic stenosis, how it can be imaged, and how these approaches might be used to track myocardial health and improve
the timing of aortic valve replacement. (J Am Coll Cardiol Img 2019;12:283–96) © 2019 The Authors. Published by
Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).A ortic stenosis is one of the most commonvalvular diseases in the Western world (1,2),with an estimated prevalence as high as
12.4% in the elderly (3). Aortic stenosis is character-
ized not only by progressive valve obstruction, but
also by the left ventricular remodeling response (4).
Narrowing of the valve causes pressure overload of
the left ventricle and triggers a hypertrophic response
that maintains myocardial performance for many
years, if not decades. However, with time, this pro-
cess decompensates as patients transition fromN 1936-878X
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Aortic stenosis progresses inexorably. Although
the early stages are asymptomatic and associated
with a good prognosis, advanced disease is associated
with substantial morbidity and mortality (5–7).
Despite much research, to date there are no proven
medical therapies that slow disease progression. The
only definitive treatment for severe aortic stenosishttps://doi.org/10.1016/j.jcmg.2018.11.026
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ABBR EV I A T I ON S
AND ACRONYMS
AVR = aortic valve
replacement
CI = confidence interval
CMR = cardiac magnetic
resonance
CT = computed tomography
ECV% = extracellular volume
fraction
HR = hazard ratio
iECV = indexed extracellular
volume
LGE = late gadolinium
enhancement
SAVR = surgical aortic valve
replacement
TAVR = transcatheter aortic
valve replacement
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284remains AVR, either by surgical aortic valve
replacement (SAVR) or transcatheter aortic
valve replacement (TAVR) approaches. The
uptake of TAVR has grown exponentially
(3,8), as interventions that were initially
offered only to elderly, inoperable patients
are now being performed in younger, lower-
risk patients with excellent results (9–13).
Decisions about if, when, and how to inter-
vene have therefore become increasingly
complex, requiring careful assessment of in-
dividual patients within a multidisciplinary
heart team.
Current guidelines recommend interven-
tion in patients with severe aortic stenosis
and evidence of left ventricular decompen-
sation. Most commonly this is in the form of
development of typical symptoms, but other
markers include a reduction in ejectionfraction <50%, an abnormal exercise tolerance test,
or a rise in brain natriuretic peptide levels (14,15).
Unfortunately, symptoms are often difficult to iden-
tify in the elderly comorbid patients encountered in
clinical practice, and many of the other changes
appear only late in the course of the disease after
irreversible myocardial damage has become estab-
lished. European Society of Cardiology guidelines
provide a Class 1 recommendation, Level of Evidence:
B, for intervention in the most common scenario—
symptomatic, severe aortic stenosis. However, inter-
vention in asymptomatic patients with a reduction in
ejection fraction <50% or an abnormal exercise test is
only Level of Evidence: C (i.e., expert opinion) (15).
The American College of Cardiology and American
Heart Association guidelines are largely in alignment
(14). This highlights the need for more robust data to
better risk-stratify patients and optimize manage-
ment strategies before the onset of symptoms and
heart failure.
Consequently, there is extensive interest in iden-
tifying novel, objective markers of early left ventric-
ular decompensation to optimize the timing of AVR
and track myocardial health over time. The develop-
ment of such markers requires improved under-
standing of the pathophysiology underling left
ventricular decompensation in aortic stenosis. His-
tological studies have suggested that myocardial
fibrosis and cell death are both important drivers of
this process (16,17). Attention has focused on
myocardial fibrosis in particular, given its structure-
function correlation with heart failure and the fact
that it can now be identified reliably and non-
invasively with modern imaging techniques. This re-
view will discuss the pathophysiology of myocardialfibrosis and left ventricular decompensation in aortic
stenosis, the imaging techniques that can be used to
detect it, and how these might be employed to track
myocardial health and optimize the timing of AVR.
PATHOLOGY
It is useful to consider aortic stenosis as a disease of
both the valve and the myocardium (4). In addition,
the importance of arterial stiffness and systemic
pulsatile arterial load cannot be underestimated in
this elderly population (18,19). A detailed discussion
of events within the valve is beyond the scope of this
review (20); however, an understanding of the path-
ological factors driving the hypertrophic remodeling
response and its subsequent decompensation are
critical to understanding the rationale for myocardial
fibrosis imaging (Central Illustration).
Progressive valve narrowing causes pressure
overload of the left ventricle and triggers a hyper-
trophic response that maintains wall stress and left
ventricular performance for many years. Over time,
this process decompensates and patients transition
from hypertrophy to heart failure, leading to adverse
clinical outcomes. This evolution is complex but is
closely related to the development of myocardial
fibrosis, myocyte injury, and cell death. Furthermore,
there is adverse remodeling of the extracellular ma-
trix, with degradation and disruption of the matrix
structure (21). These changes are regulated by several
factors, including the renin-angiotensin-aldosterone
system, transforming growth factor beta, apoptosis
signal-regulating kinase 1, and tissue inhibitor of
metalloproteinase (22–24): all potential targets for
novel therapeutic interventions.
Two distinct myocardial fibrosis patterns have
been described. Reactive interstitial fibrosis is diffuse
and follows increased myofibroblast activity and
collagen deposition that begins even in the early
stages of aortic stenosis. Importantly, this diffuse
fibrosis is reversible and has been demonstrated to
regress following AVR (16). In contrast, replacement
fibrosis appears to occur later and is irreversible (25).
Treibel et al. (26) recently demonstrated that patients
with advanced disease undergoing AVR manifest a
complex combined pattern of both replacement and
diffuse fibrosis. Moreover, they observed a fibrosis
gradient from the subendocardium to the mid-
myocardium, perhaps suggesting supply-demand
ischemia as a contributing factor.
The degree of myocardial remodeling and fibrosis
is closely related to hemodynamic markers of
myocardial performance, such as end-diastolic pres-
sure and ejection fraction (4). Moreover, multiple
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Schematic of the left ventricular remodeling response in aortic stenosis, describing the transition from hypertrophy to fibrosis, heart failure, and cardiac death.
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285histological studies have now demonstrated an asso-
ciation between myocardial fibrosis at the time of
AVR and both impaired recovery of left ventricular
systolic function and poor long-term outcomes
following valve replacement (17,27–29). Although it is
certainly plausible that myocardial fibrosis might
directly contribute to such outcomes, a causal
relationship is yet to be demonstrated.
IMAGING MODALITIES FOR THE ASSESSMENT
OF MYOCARDIAL FIBROSIS
Although myocardial biopsy and histological analysis
are still considered the gold standard assessments of
myocardial fibrosis, they have several important
limitations precluding their routine clinical applica-
tion. Myocardial biopsy is an invasive procedure
that carries an attendant risk of complications (30).
Additionally, as only small areas of the myocardium
can be sampled, biopsy is prone to sampling error. By
contrast, modern imaging techniques, in particular
those provided by cardiovascular magnetic resonance
(CMR), allow comprehensive, noninvasive assess-
ments of fibrosis across the entire myocardium as
well as quantification of its functional consequences(Table 1). These approaches have been used to assess
myocardial fibrosis in a range of cardiovascular
conditions including aortic stenosis and are described
in the following text.
CARDIAC MAGNETIC RESONANCE. CMR provides
unparalleled soft tissue characterization and can be
used to identify and measure both diffuse and
replacement forms of fibrosis in a single scan without
the use of ionizing radiation. When utilized together,
the CMR techniques described in the following
text offer the best available method of capturing
the full spectrum of fibrotic changes within the left
ventricular myocardium (26).
Late gadolinium enhancement. Gadolinium-based
contrast agents (GBCAs) partition into areas of
extracellular expansion (myocardial edema, necrosis,
infiltration, or fibrosis). Interpretation of delayed
imaging using GBCAs requires clear differences in
signal intensity between healthy and diseased
myocardium in a relatively discrete distribution.
Consequently, late gadolinium enhancement (LGE) is
an excellent marker of focal replacement fibrosis,
but is insensitive for the detection of more diffuse
interstitial fibrosis.










TTE þþþ þþþ - - þþþ
CT þþ þþ þ þ þ
CMR þ þþþ
Native T1 þþ þ þ
ECV%/iECV þþ þ þ
LGE - þþþ þþþ
FT - þþþ - - þ
CMR ¼ cardiac magnetic resonance; CT ¼ computed tomography; ECV% ¼ extracellular volume fraction;
FT ¼ feature tracking; iECV ¼ indexed extracellular volume; LGE ¼ late gadolinium enhancement;
TTE ¼ transthoracic echocardiogram.
FIGURE 1 Late Gad
A
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286LGE is now well established and widely used as a
method for detecting replacement myocardial fibrosis
in a broad range of cardiovascular conditions such as
ischemic cardiomyopathy, nonischemic dilated car-
diomyopathy, cardiac sarcoidosis, cardiac amyloid-
osis, myocarditis, and hypertrophic cardiomyopathy
(31–38). In each condition, replacement fibrosis
detected by LGE serves as an independent and
powerful predictor of mortality and adverse cardio-
vascular events. LGE is also the most studied and bestolinium Enhancement Patterns in Aortic Stenosis
CB
ort-axis (top) and corresponding long-axis (bottom) late gadolinium images f
ent typical of the replacement fibrosis seen in aortic stenosis. (D) Subendo
due to infarction rather than focal noninfarct fibrosis. Areas of infarction such
indicate areas of late gadolinium enhancement.validated imaging method for detecting myocardial
fibrosis in aortic stenosis. Multiple independent
studies have described a noninfarct (or mid-wall)
pattern of LGE in patients with aortic stenosis that
is distinct from the pattern of scarring seen in other
pathologies such as myocardial infarction (Figure 1).
On histology, noninfarct LGE co-localizes with
microscars and replacement fibrosis, whereas clinical
studies have validated it against other markers of left
ventricular decompensation and demonstrated a
close association with advanced left ventricular hy-
pertrophy, increased myocardial injury, electrocar-
diographic changes, impaired diastolic and systolic
function, and reduced exercise capacity (25,39–41).
Once noninfarct LGE becomes established, it pro-
gresses rapidly. Although the process is arrested
by aortic valve intervention, replacement fibrosis
appears irreversible once established. Thus, the
burden of replacement fibrosis a patient accumulates
while waiting for valve intervention persists with
them until death (42). The clinical implications are
important, as noninfarct LGE is associated with a poor
long-term prognosis. Indeed, 5 studies and a recent
meta-analysis (43) have confirmed noninfarct LGE
to be an independent predictor of mortality, ofD
rom cardiac magnetic resonance scans. (A to C) Focal noninfarct late
cardial late gadolinium enhancement in coronary artery territories,
as these should be excluded when calculating extracellular volume
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287incremental value to valve assessments, comorbidity,
and left ventricular ejection fraction (28,41,44–46)
(Table 2).
The poor prognosis associated with non-infarct
LGE appears to persist long after AVR is performed,
in keeping with the irreversible nature of replacement
fibrosis. In the largest study to date, the British
Society for Cardiovascular Magnetic Resonance Valve
Consortium performed comprehensive CMR assess-
ments in over 650 patients with severe aortic stenosis
just prior to SAVR or TAVR (46). At a median follow-
up of 3.6 years, LGE (present in 50% of patients)
was a powerful independent predictor of all-cause
(26.4% vs. 12.9%; p < 0.001) and cardiovascular
mortality (15.0% vs. 4.8%; p < 0.001) following
AVR. Furthermore, this association appeared
dose-dependent: with every 1% increase in left
ventricular myocardial scar burden, all-cause and
cardiovascular mortality increased by 11% and 8%,
respectively (hazard ratio [HR]: 1.11; 95% confidence
interval [CI]: 1.05 to 1.17; p < 0.001; and HR: 1.08;
95% CI: 1.01 to 1.17; p < 0.001). Similar effects
were observed for both infarct and noninfarct LGE.
Noninfarct LGE was also demonstrated to be an
independent predictor of both all-cause and cardio-
vascular mortality.
LGE is reliable, well-validated, and easily inte-
grated into the standard workflow, with post-
processing and qualitative analysis
readily performed in <10 min in most cases. LGE is
therefore ready for investigation as a tool for use
in routine clinical practice. Indeed, the ongoing
EVOLVED (Early Valve Replacement Guided by
Biomarkers of Left Ventricular Decompensation in
Asymptomatic Patients with Severe Aortic Stenosis)
trial (NCT03094143) (47) will investigate whether
patients in whom noninfarct LGE is identified may
benefit from early AVR before further fibrosis
develops and left ventricular decompensation
progresses (see the Future Directions section).
T1 mapping. Although LGE is now well-established as a
marker of replacement fibrosis, this technique is not
able to detect the diffuse interstitial fibrosis that
also characterizes left ventricular decompensation
in aortic stenosis. Moreover, LGE quantification can
be challenging in diffuse fibrotic states. Novel CMR
T1 mapping approaches have been developed to
overcome these issues. These are reviewed in depth
elsewhere (48,49), but in brief, parametric T1 maps
are produced where the tissue T1 time is encoded
as signal intensity within each voxel on a static
2-dimensional image and converted to color maps to
aid visual interpretation (Figure 2). Native T1 values
reflect the state of both the intracellular andextracellular environments, while the addition of a
GBCA facilitates targeted interrogation of the extra-
cellular space.
Various protocols for T1 mapping have been stud-
ied (49). The original Look-Locker technique (50) has
been largely superseded by modern variations. The
modified Look-Locker imaging sequence (51) is the
most studied inversion-recovery technique, whereas
variants such as the shortened modified Look-Locker
imaging sequence require a shorter breath hold (52).
Optimization of protocols has improved accuracy,
acquisition time, and ease of use via reduction in
heart rate dependence and breath holds. Moreover,
post-processing and analysis of T1 mapping data can
now be performed with fast and reproducible tech-
niques utilizing standardized protocols. T1 mapping
techniques are now readily accessible in many CMR
units and will be discussed below.
Native T1. As fibrosis increases, native T1 values
increase. Quantitative T1 measurements therefore
allow detection of focal or diffuse fibrosis without the
use of GBCAs, although the T1 signal also changes
with other pathological processes such as edema or
myocardial infiltration. Native T1 has been utilized
in conditions such as myocardial infarction, myocar-
ditis, dilated cardiomyopathy, cardiac amyloid, and
Fabry disease (48), and has demonstrated significant
prognostic power beyond that of LGE alone (53,54).
Although less robust, data is also emerging for native
T1 in aortic stenosis. Recent studies have demon-
strated a correlation between native T1 and both the
degree of diffuse fibrosis on histology and the extent
of ventricular remodeling on CMR (55–57) (Table 2).
Lee et al. (58) recently presented a single-center
cohort of 127 patients with moderate or severe AS in
whom native T1 was an independent predictor of
heart failure hospitalization or death (2.4% vs. 11.6%
vs. 42.9% for low, mid, and high tertiles of native T1,
respectively; p < 0.001).
Although native T1 is relatively uniform and
reproducible when using the same sequence and
scanner on the same patient, values are subject to
a variety of factors such as patient age and sex,
acquisition sequence, scanner field strength, and
post-processing. In aortic stenosis, even within the
same scanner and protocol, substantial overlap exists
in T1 values across different severities of aortic
stenosis and with healthy control subjects (59).
Consequently, there are no universal cutoffs for
health and disease in aortic stenosis (60). The Inter-
national T1 Mapping Multicenter Consortium (61) has
successfully standardized a multivendor sequence
and provided valuable diagnostic and prognostic data
in other disease states. However, although native T1
TABLE 2 CMR Studies Investigating Myocardial Fibrosis in Aortic Stenosis
Study (Ref. #) Year n Population CMR Biopsy Findings
Native T1 Studies
Bull et al. (55) 2013 109 Severe AS undergoing SAVR




19 Native T1 correlated with CVF (r ¼ 0.65; p ¼ 0.002) and
increased with disease severity.





20 Native T1 correlated with histology (r ¼ 0.777; p < 0.001)
and TTE measures of diastolic dysfunction, and was
increased compared with control patients, with overlap.
ECV Studies




18 ECV% correlated with CVF (r2 ¼ 0.86; p < 0.001).




18 ECV% correlated with CVF (r2 ¼ 0.685). ShMOLLI was superior
to FLASH-IR.




18 ECV% by both methods correlated with CVF
(r2 ¼ 0.69; p < 0.01 and r2 ¼ 0.71; p < 0.01).




— ECV% was increased compared with control subjects, with
overlap. At 6 months, LVH had regressed but diffuse
fibrosis was unchanged.
LGE Studies
Weidemann et al. (27) 2009 46 Severe AS undergoing AVR LGE 46 LGE appeared to be concordant with histology (88% with
severe fibrosis had $2 positive segments; 89% with no
fibrosis had no positive segments) and did not regress at
9 months post-AVR.
Azevedo et al. (28) 2010 28 Severe AS undergoing AVR 1.5-T
LGE
28 LGE was present in 61%.
LGE correlated with histology (r ¼ 0.67; p < 0.001).
LGE was an independent predictor of all-cause mortality
(HR: 1.26; 95% CI: 1.03–1.54; p ¼ 0.02).
Debl et al. (79) 2006 22 Symptomatic AS 1.5-T
LGE
— LGE was present in 27%.
LGE correlated with more severe AS and LVH.
Rudolph et al. (80) 2009 21 Any AS 1.5-T
LGE
— LGE was present in 62%.
LGE correlated with increased LV mass and end-diastolic
volume index.
Dweck et al. (44) 2011 143 Moderate or severe AS 1.5-T
LGE
— LGE present in 66%.
Midwall LGE present in 38%.
Midwall LGE was an independent predictor of all-cause
mortality (HR: 5.35; 95% CI: 1.16–24.56; p ¼ 0.03).
Baron-Rochette et al.
(45)
2014 154 Severe AS undergoing AVR 1.5-T
LGE
— LGE present in 29%.
LGE was an independent predictor of all-cause mortality
(HR: 2.8; 95% CI: 1.1 to 6.9; p ¼ 0.025).
Rajesh et al. (81) 2017 109 Severe AS 1.5-T
LGE
— LGE present in 43%.
Midwall LGE present in 31%.
LGE predicted heart failure/hospitalization and a fall in
LVEF but did not predict mortality.
Musa et al. (46) 2018 674 Severe AS undergoing AVR 1.5-T, 3-T
LGE
— LGE present in 51%.
Noninfarct LGE present in 33%.
Scar associated with all-cause (26.4% vs 12.9%; p < 0.001)
and cardiovascular (15.0% vs 4.8%; p < 0.001) mortality
in a dose-dependent fashion (for every 1% increase in scar,
HR: 1.11; 95% CI: 1.05–1.17; p < 0.001 for all-cause and HR:
1.08; 95% CI: 1.01–1.17; p < 0.001 for cardiovascular
mortality).
Infarct and noninfarct scar were both associated with adverse
outcomes.





12 LGE was present in 17 of 31 patients (from total cohort).
Only ECV% correlated with histology (r ¼ 0.79; p ¼ 0.011).




31 Patient with severe MF (>30%) on histology had higher native
T1 times and ECV%. Native T1 $1,010 ms and ECV $0.32
had AUC of 0.82 and 0.85, respectively, for severe MF.
Continued on the next page
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TABLE 2 Continued
Study (Ref. #) Year n Population CMR Biopsy Findings




11 Midwall LGE was present in 27%.
iECV correlated with histology (r ¼ 0.87; p < 0.001) and was
increased compared with control subjects.
iECV þ LGE predicted unadjusted all-cause mortality (36 vs.
8 deaths/1,000; p ¼ 0.009).




133 LGE was present in 60%; noninfarct pattern was more
common.
Complex MF patterns. LGE, but not ECV%, correlated with CVF
in all biopsies (r2 ¼ 0.28; p < 0.001) but more in biopsies
with endocardium (r2 ¼ 0.501; p < 0.001). Combined
LGE þ ECV% best predicted LV remodeling and functional
capacity.






12 Noninfarct LGE was present in 20%.
Sequences differed in discrimination between health and
disease as well as association with CVF. Native T1 with
MOLLI correlated best (r ¼ 0.582; p ¼ 0.027).




— ECV displayed excellent scan-rescan reproducibility and was
higher in AS than control subjects. Native T1 was not as
reproducible and was not significantly higher in AS than
control subjects.
Chin et al. (40),
Shah et al. (39)




— Midwall LGE was present in 28%.
ECV% and LGE were associated with elevated TnI and ECG
evidence of strain.




— LGE was present in 24%.
ECV% was increased compared to control patients and
correlated with TTE measures of diastolic dysfunction.




— At 1 yr, cellular and matrix volume regressed. LGE was
unchanged.





— Midwall LGE was present in 26%.
LGE progressed from baseline and was most rapid in patients
with more severe stenosis.
In patients undergoing AVR, iECV reduced by 11% (4%–16%)
but there was no change in LGE.




— LGE was present in 32.3%.
Native T1 was increased compared with control patients,
with overlap.
Native T1 and LGE were independent predictors of poor
prognosis.
AS¼ aortic stenosis; AUC ¼ area under the curve; CI ¼ confidence interval; CMR ¼ cardiac magnetic resonance; CVF ¼ collagen volume fraction; DynEQ-CMR ¼ dynamic equilibrium contract-cardiac magnetic
resonance; ECV% ¼ extra-cellular volume fraction; EQ-CMR ¼ equilibrium contrast cardiac magnetic resonance; FLASH-IR ¼ fast low angle single shot inversion recovery; HR ¼ hazard ratio; iECV ¼ indexed
extracellular volume; LGE ¼ late gadolinium enhancement; LVEF ¼ left ventricular ejection fraction; LVH ¼ left ventricular hypertrophy; MOLLI ¼ modified Look-Locker inversion recovery; SASHA ¼
saturation recovery single-shot acquisition; SAVR¼ surgical aortic valve replacement; shMOLLI¼ shortened modified Look-Locker inversion recovery; TnI ¼ troponin I; TTE¼ transthoracic echocardiography.
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289holds major appeal as a marker of diffuse fibrosis that
does not require contrast administration and is
favored as a technique by various experts in the field,
its specific role in aortic stenosis requires further
research.
Post-contrast T1 mapping. GBCAs do not cross cell
membranes and therefore distribute throughout
the extracellular space in the myocardium. Post-
contrast T1 mapping techniques therefore allow
more specific interrogation of the extracellular
space due to gadolinium’s shortening effects on T1
relaxation times. Unfortunately, standardization
of post-contrast T1 mapping values is difficult due to
variation in gadolinium kinetics between patientsand even within the same individual on different
days. Standardized normal values are again lacking,
and consequently, post-contrast T1 mapping is not
in widespread use.
Extracellular volume fraction. The extracellular volume
fraction (ECV%) corrects post-contrast myocardial T1
mapping values for blood pool and pre-contrast
myocardial T1, thereby accounting for differences in
blood concentrations of GBCAs. By incorporating the
hematocrit, ECV% calculates the fraction of the
myocardium comprised by the extracellular space
according to the formula ECV% ¼ (D[1/T1myo]/D[1/
T1blood])  (1  hematocrit), where D(1/T1) is the
difference in myocardial or blood T1 pre- and
FIGURE 2 T1 Mapping












































Three different cardiac magnetic resonance T1 maps are demonstrated. Native T1 and post-contrast T1 maps are generated by the signal intensity encoded within each
voxel, depending on the T1 relaxation time; color coding according to T1 times is applied for visual reference. ECV% maps are generated using the formula ECV% ¼
(D[1/T1myo]/D[1/T1blood])  (1  hematocrit), where D(1/T1) is the difference in myocardial or blood T1 pre-contrast and post-contrast. ECV% can be used to assess the
proportion of the myocardium comprised by extracellular space. Note that there is significant overlap between health and disease with native and post-contrast T1, in
contrast to ECV%. Graphs adapted from Chin et al. (59) by permission of Oxford University Press. ECV% ¼ extracellular volume fraction; iECV ¼ indexed extracellular
volume.
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290post-contrast (62). A key feature of myocardial
fibrosis is the deposition of excess collagen in the
interstitial space and the subsequent expansion of the
extracellular space. ECV% has therefore been inves-
tigated as a method for detecting diffuse myocardial
fibrosis in a range of cardiovascular conditions
including myocardial infarction, nonischemic car-
diomyopathy, and aortic stenosis (63,64).
Current scanning techniques assume a dynamic
equilibrium between blood and myocardium w10 to
15 mins after a bolus injection of contrast (65,66). A
synthetic ECV% has also been described that derives
hematocrit from the longitudinal relaxation rate of
blood, obviating the need for blood sampling (67),
while a more recent noninvasive point-of-care probe
to derive hematocrit has demonstrated promising
results when compared with both standard and syn-
thetic ECV% (68). ECV% has thus become easier to
measure and more clinically applicable. Moreover,ECV% potentially corrects for differences in T1 values
on different scanners and sequences, making it
appealing as a technique for multicenter research.
A number of clinical studies have validated ECV%
against histology in aortic stenosis and have demon-
strated the association between ECV% and other
markers of LV decompensation, including ECG
changes of hypertrophy and strain and elevation
in biomarkers such as troponin and N-terminal
pro-brain natriuretic peptide (26,39–41) (Table 2).
ECV% also demonstrates excellent scan-rescan
reproducibility (59), while guidelines to standardize
post-processing have been developed and recom-
mend that areas of noninfarct LGE are included and
areas of infarct LGE excluded from regions of interest
in ECV% calculation (69). However, data assessing the
prognostic value of ECV% in aortic stenosis are
limited, and overlap between disease groups is again
observed. In addition, the effect of AVR on ECV%
FIGURE 3 iECV calculation
iECV: Biomarker of the Total Myocardial Fibrosis
































Cut off for  extracellular expansion
ECV% = (Δ(1/T1myo) / Δ(1/
T1blood)) × (1 - hematocrit)
iECV = myocardial volume
indexed to BSA × ECV%
The cardiac magnetic resonance short-axis images provide examples of the pre-contrast and post-contrast contours required to calculate
iECV. Systolic and diastolic contours are drawn using the short-axis stack to calculate myocardial volume, which is necessary to derive iECV.
Color look-up tables have not been applied to the T1 images. iECV provides a surrogate of the total myocardial fibrosis burden according to the
formula demonstrated in the figure. iECV demonstrates good correlation with histological fibrosis burden and severity of aortic stenosis.
Graph adapted from Chin et al. (41), Creative Commons Attribution License: https://creativecommons.org/licenses/by/4.0/. BSA ¼ body
surface area; other abbreviations as in Figure 2.
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291may be somewhat counterintuitive as values can in-
crease after surgery—a weakness of assessing the
extracellular component of the myocardium as a
fraction of the ventricular mass when both the
intracellular and extracellular compartments are un-
dergoing reverse remodeling (25).
Indexed extracellular volume. Whereas ECV% provides
a percentage estimate, the indexed extracellular
volume (iECV) quantifies the total left ventricular
extracellular myocardial volume indexed to body
surface area by multiplying ECV% by the indexed left
ventricular myocardial volume: iECV ¼ ECV% 
indexed left ventricular myocardial volume (Figure 3).
Furthermore, cellular volume can be calculated:
(1  ECV%)  left ventricular volume). This can also
be indexed to body surface area. In combination with
LV mass, ECV% and iECV can together provide an
understanding of ventricular remodeling and reverse
remodeling with respect to both the cellular and
extracellular myocardial compartments. Two studies
have utilized iECV or matrix volume as a novel
assessment of myocardial fibrosis burden (25,41),
with iECV demonstrating a close association with
histological fibrosis assessments. Importantly, iECV
appears to provide greater discrimination between
disease states than other T1 mapping parameters.Chin et al. (41) demonstrated that a threshold of
22.5 ml/m2 (derived from 37 age- and sex-matched
healthy volunteers and defined as 2 SDs above the
mean) could be used to differentiate healthy
myocardium from diseased myocardium infiltrated
by diffuse fibrosis, and in doing so, identify patients
with early evidence of left ventricular decompensa-
tion and adverse long-term outcome (41).
iECV and ECV% have recently been used in
combination to study changes in the composition of
the intracellular and extracellular compartments
before and after AVR. This has provided important
insights into left ventricular remodeling and reverse
remodeling after relief of loading conditions.
Changes in iECV are not accounted for by changes in
total left ventricular mass alone. Prior to AVR, iECV
(representing total extracellular matrix, or fibrosis,
burden) and left ventricular mass appear to increase
in a broadly balanced manner so that ECV% remains
largely unchanged. Following AVR, left ventricular
mass decreases. Cellular and extracellular mass
regress, but cellular mass regresses more rapidly,
thereby resulting in an apparently paradoxical in-
crease in ECV% as the ratio of matrix to total mass is
increased (25,42). iECV, however, decreases as it
represents the extracellular matrix as a total volume,
FIGURE 4 Schematic for the Development of Myocardial Fibrosis in Aortic Stenosis
and Response to AVR
Time





LV Cellular Mass Diffuse Fibrosis Replacement Fibrosis
AVR
As aortic stenosis progresses, left ventricular (LV) mass gradually increases, followed
by the development of diffuse fibrosis. Replacement fibrosis occurs later but accelerates
rapidly once established. Following relief of pressure-loading conditions after aortic valve
replacement (AVR), LV cellular mass and extracellular matrix both regress at different
rates. The burden of replacement fibrosis, however, persists. The insets show short-
axis cardiac magnetic resonance late gadolinium enhancement imaging slices of a patient
with aortic stenosis. At baseline, there is focal late gadolinium enhancement representing
discrete focal replacement fibrosis (white arrow). After 1 year, the burden of this
replacement fibrosis has increased with the development of several new discrete
deposits (red arrows). The patient subsequently underwent AVR. One year later,
despite regression of LV mass, there is no regression of replacement fibrosis
(white arrows).
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292rather than a percentage. The reduction in iECV is
therefore in keeping with the potential for reversal
of diffuse fibrosis. This effect has been confirmed
independently by 2 different groups in separate co-
horts and stands in contrast to the irreversible na-
ture of replacement fibrosis as assessed by LGE
(Figure 4). iECV requires further exploration and
validation but is a promising method to track
myocardial fibrosis.
In summary, T1 mapping is an exciting and
emerging research field in aortic stenosis research
that provides the only method of identifying revers-
ible diffuse myocardial fibrosis. It holds particular
potential as a method to track myocardial health over
time, with important clinical implications. Standard-
ization of sequences and protocols have resulted in
reproducible and powerful prognostic T1 mapping
data in a variety of myocardial disease states
(41,53,54,58). However, T1 mapping in aortic stenosis
is in a relatively early stage of development. Further
work is required to establish validated thresholds to
aid decision making, paving the way for futuremulticenter prognostic studies that are ultimately
required. Of the T1 mapping parameters currently in
use, we believe that ECV% and iECV currently pro-
vide the most complete understanding of cellular and
extracellular remodeling in aortic stenosis, although
native T1 provides important advantages, particularly
with regard to ease of calculation and the avoidance
of contrast administration.
OTHER IMAGING MODALITIES. Alternative imaging
techniques to assess myocardial fibrosis in aortic
stenosis are limited. Research into computed tomog-
raphy (CT) assessments of myocardial fibrosis re-
mains exploratory, with only limited data available
that has largely focused on measuring ECV on CT
scans performed after the administration of iodinated
contrast agents (Table 3). These techniques are
worthy of further investigation given the widespread
use of CT imaging in patients being considered for
TAVR and the emerging utility of CT calcium scoring
as a marker of stenosis severity. Strain imaging on
echocardiography or CMR can be a valuable nonin-
vasive tool to evaluate and quantify myocardial
deformation before any identifiable changes in ejec-
tion fraction; however, despite an association with
imaging markers of myocardial fibrosis (27,29) and
potential prognostic utility (70,71), this approach is
unable to measure myocardial fibrosis directly.
FUTURE DIRECTIONS
Myocardial fibrosis is well established as a hallmark
pathological feature of left ventricular decompensa-
tion in patients with aortic stenosis; yet, it is
not routinely assessed in clinical practice. In part, this
has reflected the limitations of myocardial biopsy,
many of which have now been overcome with
advanced noninvasive imaging. The next step is to
assess whether these imaging techniques will prove
of clinical value in monitoring myocardial health,
identifying left ventricular decompensation, and
optimizing the timing of AVR.
LGE is the best validated of these approaches, is
relatively simple to perform and analyze, and is
supported by powerful prognostic data. Whether
noninfarct LGE can be used to optimize the timing of
valve intervention is currently being tested in
the EVOLVED (Early Valve Replacement Guided by
Biomarkers of LV Decompensation in Asymptomatic
Patients With Severe AS) trial (NCT03094143) (47)
(Figure 5). This multicenter randomized controlled
trial will recruit asymptomatic patients with severe
aortic stenosis for CMR imaging. Those patients with
noninfarct LGE will then be randomized 1:1 to early
valve intervention (SAVR or TAVR) versus the
FIGURE 5 Proposed Integration of Myocardial Fibrosis Into the Classical Description














EVOLVED - early AVR
Routine AVR
Adaption of the outcome curve originally proposed by Braunwald in 1968 (76). Prior to
the onset of symptoms, there is a long latent period in aortic stenosis where subclinical
myocardial changes take place, including the development of reversible diffuse fibrosis
followed by irreversible replacement fibrosis. These changes may be assessed with the
imaging modalities denoted in the figure. Exploratory data suggest that diffuse fibrosis
is associated with an adverse long-term outcome in aortic stenosis. The prognostic data
related to the noninfarct pattern of late gadolinium enhancement (LGE) as a marker of
replacement fibrosis is comparatively robust, establishing LGE as a powerful indepen-
dent predictor of long-term clinical outcomes. According to current guidelines and
routine clinical practice, AVR is performed after the onset of symptoms. Future and
ongoing trials, including the EVOLVED trial, are required to determine whether targeted
early intervention utilizing cardiac magnetic resonance (CMR) to detect fibrosis will lead
to improved clinical outcomes. Abbreviations as in Figures 2 and 4.
TABLE 3 CT to Detect Myocardial Fibrosis
Study (Ref. #) Year n Population CT Biopsy CMR Findings
Bandula et al. (85) 2013 23 Severe AS undergoing SAVR Iohexol equilibrium
bolus and
infusion protocol
23 shMOLLI ECVCT correlated with ECVCMR (r ¼ 0.73; p < 0.001)
and histological fibrosis (r ¼ 0.71; p < 0.001).







ECVCT correlated with ECVCMR (r ¼ 0.89;
p < 0.001) and histological fibrosis (r ¼ 0.925;
p < 0.001).
Treibel et al. (87) 2017 73 Validation cohort:
28 severe AS 27 amyloid
18 severe AS underdoing SAVR
64-detector
Iohexol bolus
18 — Good correlation between synthetic and
conventional ECVCT (r
2 ¼ 0.96; p < 0.001).
Good correlation between synthetic and
conventional ECVCT and histology (both
r2 ¼ 0.50; p < 0.001).
ECVCT was higher in amyloidosis.






Correlation between CMR and CT (r ¼ 0.82;
p < 0.001).
ECV lower in healthy patients for both CMR and
CT (p ¼ 0.03).





— — Mean 3D ECV significantly higher in HFrEF than
other groups (p ¼ 0.02).




— 1.5-T shMOLLI ECVCT at 5 min and 15 min correlated with ECVCMR
(r2 ¼ 0.85; r2 ¼ 0.74; p < 0.001).
ECVCT was higher in amyloidosis and correlated
with markers of severity.









Good agreement between ECVCT and ECVCMR on
per-subject (Bland-Altman bias 0.06%; 95% CI:
1.19–1.79) and per-segment level.
CT ¼ computed tomography; DCM ¼ dilated cardiomyopathy; HF ¼ heart failure; HFpEF ¼ heart failure with preserved ejection fraction; HFrEF ¼ heart failure with reduced ejection fraction; other ab-
breviations as in Table 2.
J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 1 2 , N O . 2 , 2 0 1 9 Bing et al.
F E B R U A R Y 2 0 1 9 : 2 8 3 – 9 6 Imaging and Impact of Myocardial Fibrosis in Aortic Stenosis
293conventional approach of watchful waiting until
symptom development or clinical heart failure. To
mitigate the costs of CMR, patients will initially be
screened with high-sensitivity troponin and an elec-
trocardiogram, both of which are predictors of non-
infarct LGE (72); only those patients with an abnormal
electrocardiogram or a troponin $6 ng/l will proceed
to CMR. The primary endpoint is a composite of
all-cause mortality and unplanned aortic stenosis–
related hospital admissions. This is the first random-
ized trial to offer targeted early intervention in
patients with myocardial fibrosis and left ventricular
decompensation, and the results will be of great in-
terest. Similar randomized controlled trials will ulti-
mately be required to establish the clinical utility of
other myocardial fibrosis assessments, given that
aortic valve intervention is not without risk.
CMR assessments of diffuse fibrosis in aortic ste-
nosis require further validation but offer the potential
to identify the earlier stages of myocardial disease
and track myocardial health with time. T1 mapping is
the only available imaging technique that is able to
offer an assessment of diffuse fibrosis, and as such, it
is crucial that ongoing research is conducted to pro-
vide standardization of sequences and protocols
across sites and vendors to delineate clear cutoffs for
health and disease in aortic stenosis. As T1 mapping
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294research expands, this approach may offer clear ad-
vantages over LGE. For example, future investigation
of antifibrotic therapies will require biomarkers to
monitor myocardial health and treatment effects; T1
mapping will be indispensable in this regard.
Further work to investigate the role of emerging
CT techniques is also warranted, particularly as
they may be more easily integrated into current
clinical care pathways and workflows than
CMR. There has also been early investigation of
collagen- and elastin-specific CMR contrast agents,
which may provide greater contrast to noise ratio
compared with current GBCAs, but further advances
in this field are awaited (73,74). Finally, there is
considerable interest in developing novel positron-
emission tomography tracers to measure myocar-
dial fibrosis activity, in contrast to the structural
and functional assessments that have been devel-
oped to date. We await further studies to demon-
strate this potential. As interest in this field
progresses and new techniques emerge, it is of
course important to be cognizant of publicationbias, which remains an issue in the published
medical data (75).
CONCLUSIONS
Myocardial fibrosis plays a key role in the patho-
physiology of aortic stenosis. Modern imaging tech-
niques now allow assessment of both replacement
and diffuse interstitial fibrosis as well as their func-
tional consequences. These techniques hold promise
in tracking myocardial health in patients with aortic
stenosis, aiding risk stratification and potentially
optimizing the timing of aortic valve intervention,
with ongoing trials currently testing the clinical effi-
cacy of these approaches.
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